Paper Details

  1. Home
  2. Paper Details

Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation.

Author: MickR, RaiK, SawitskyA, ShapiroL, ShustikC, SilverR

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study compared the effectiveness of early treatment with chlorambucil to no treatment for 59 patients with early-stage chronic lymphocytic leukemia (CLL). After 5 years, there was no significant difference in survival between the groups. However, a higher percentage of patients in the untreated group (70%) were experiencing active disease compared to the treated group (55%). The study concludes that early treatment with chlorambucil does not improve survival for patients with early-stage CLL.
Paper Details　
Original Abstract of the Article :
The effect of early therapy on the course of chronic lymphocytic leukemia (CLL) has not been established. Fifty-nine patients with indolent Rai stage I and II CLL were randomized to receive intermittent chlorambucil once a month or to receive no treatment. The two groups were comparable in entry cha...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/hon.2900060103

データ提供：米国国立医学図書館（NLM）

Early Treatment for Chronic Lymphocytic Leukemia: To Treat or Not to Treat?

Chronic Lymphocytic Leukemia (CLL) is a complex and often unpredictable blood cancer, requiring careful consideration of treatment strategies. This study delves into the effectiveness of early treatment with chlorambucil for patients with indolent CLL. The authors conducted a randomized clinical trial, meticulously comparing the outcomes of patients receiving intermittent chlorambucil with those who opted for observation. It's like a camel embarking on a journey through a vast and uncertain desert, seeking to understand the optimal path for navigating this challenging disease.

Early Treatment and Survival in CLL

The study found no significant difference in survival between the two groups. While early treatment did not result in a survival advantage, it did lead to a lower proportion of patients exhibiting active disease 5 years after randomization. This suggests that early treatment might potentially delay disease progression, offering a valuable tool for managing the course of CLL. However, further research is necessary to clarify the long-term benefits and risks associated with early treatment.

Navigating the Treatment Decisions in CLL

This study provides valuable insights into the complex decision-making process surrounding CLL treatment. It underscores the need for careful consideration of individual patient factors, including disease stage and progression, when determining the optimal course of action. Just as a camel carefully navigates the shifting sands of a desert, clinicians must navigate the uncertainties of CLL, seeking to provide the best possible care for their patients.

Dr.Camel's Conclusion

This research sheds light on the complex landscape of CLL treatment. It's like a desert with multiple paths, each leading to different outcomes. While early treatment with chlorambucil may not always lead to a survival advantage, it may potentially delay disease progression, offering a valuable tool for managing the course of CLL. The findings emphasize the importance of ongoing research and personalized treatment approaches for this challenging disease.

Date :
  1. Date Completed 1988-04-06
  2. Date Revised 2019-10-29
Further Info :

Pubmed ID

3277904

DOI: Digital Object Identifier

10.1002/hon.2900060103

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.